Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Conversion of Preferred Stock [Member] Preferred Stock [Member]	Conversion of Preferred Stock [Member] Common Stock [Member]	Conversion of Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Preferred Stock [Member] Retained Earnings [Member]	Conversion of Preferred Stock [Member]	Conversion of Series E Preferred Stock [Member] Preferred Stock [Member]	Conversion of Series E Preferred Stock [Member] Common Stock [Member]	Conversion of Series E Preferred Stock [Member] Receivables from Stockholder [Member]	Conversion of Series E Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series E Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Series E Preferred Stock [Member] Retained Earnings [Member]	Conversion of Series E Preferred Stock [Member]	At the Market Offering [Member] Preferred Stock [Member]	At the Market Offering [Member] Common Stock [Member]	At the Market Offering [Member] Receivables from Stockholder [Member]	At the Market Offering [Member] Additional Paid-in Capital [Member]	At the Market Offering [Member] AOCI Attributable to Parent [Member]	At the Market Offering [Member] Retained Earnings [Member]	At the Market Offering [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Receivables from Stockholder [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member]	Preferred Stock [Member]	Common Stock [Member]	Receivables from Stockholder [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020																													14,000	56,003,000
Balance at Dec. 31, 2020																													$ 0	$ 56	$ 0	$ 242,672	$ (295)	$ (211,406)	$ 31,027
Net loss																													0	0	0	0	0	(45,738)	(45,738)
Foreign currency translation adjustment																													0	0	0	0	1,124	0	1,124
Stock based compensation expense																													$ 0	$ 0	0	5,215	0	0	5,215
Issuance of common stock resulting from exercise of stock options (in shares)																													0	482,000
Issuance of common stock resulting from exercise of stock options																													$ 0	$ 0	0	1,024	0	0	$ 1,024
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)																													0	64,000					64,257
Issuance of common stock resulting from purchase of employee stock purchase plan shares																													$ 0	$ 0	0	165	0	0	$ 165
Issuance of common stock resulting from exercise of warrants (in shares)																													0	1,391,000
Issuance of common stock resulting from exercise of warrants																													$ 0	$ 1	0	836	0	0	837
Issuance of common stock resulting from conversion of preferred stock (in shares)	(4,000)								(5,000,000)
Issuance of common stock resulting from conversion of preferred stock	$ 0		$ 0	$ (4)	$ 0	$ 0	$ 0	$ 0	$ (5)	$ 0	$ 5	$ 0	$ 0	$ 0
Issuance of common stock resulting from conversion of stock (in shares)		3,812,000						5,000
Issuance of common stock resulting from conversion of preferred stock (in shares)		4,000
Issuance of common stock (in shares)															0	8,180,000						0	7,290,000
Issuance of common stock															$ 0	$ 8	$ 0	$ 38,180	$ 0	$ 0	$ 38,188	$ 0	$ 8	$ 0	$ 18,905	$ 0	$ 0	$ 18,913
Balance (in shares) at Dec. 31, 2021																						16,000	72,222,000
Balance at Dec. 31, 2021																						$ 0	$ 72	$ 0	$ 306,998	$ 829	$ (257,144)	$ 50,755							50,755
Net loss																													0	0	0	0	0	(33,277)	(33,277)
Foreign currency translation adjustment																													0	0	0	0	(1,010)	0	(1,010)
Stock based compensation expense																													0	0	0	4,402	0	0	4,402
Issuance of common stock resulting from exercise of stock options																													$ 0	$ 0	0	95	0	0	$ 95
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)																													0	182,000					181,466
Issuance of common stock resulting from purchase of employee stock purchase plan shares																													$ 0	$ 0	0	197	0	0	$ 197
Issuance of common stock resulting from exercise of warrants (in shares)																													0	46,000
Issuance of common stock (in shares)																													0	2,069,000
Issuance of common stock																													$ 0	$ 2	0	6,838	0	0	6,840
Unrealized loss on investments																													$ 0	$ 0	0	0	(73)	0	(73)
Balance (in shares) at Dec. 31, 2022																													16,000	74,519,000
Balance at Dec. 31, 2022																													$ 0	$ 74	$ 0	$ 318,530	$ (254)	$ (290,421)	$ 27,929